Guardant Health grows with Shield blood CRC screening, Quest deal, 50M reach, 335% surge, and FY25 revenue $981M up 33%. Read ...
Everyday Health on MSN
Weird-Looking Stools: How Your Poop Can Signal Colon Cancer
Learn how stool appearance can signal colon cancer. Recognize signs like ribbon-like and pebble-shaped stools, and understand ...
It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...
WBRE Wilkes-Barre on MSN
Unexpected colon cancer screening test show up at your door? This may be why
According to Cologuard, made by Wisconsin-based Exact Sciences, there are three primary reasons why you may receive a testing kit in the mail without ordering it yourself: your doctor or health care ...
WASHINGTON (DC News Now) — A new blood test may make it much easier and cheaper to screen for signs of colon cancer. Test manufacturer Guardant said the Food and Drug Administration (FDA) approved its ...
INDIANAPOLIS (WISH) – This week, the United States Food and Drug Administration approved Guardant’s Shield blood test to screen for colon cancer in average-risk Americans 45 to 75 years old.
New global initiative urges patients and clinicians to wait for biomarker testing results before starting treatment.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for ...
Colon cancer is on the rise in younger people, which is why testing guidelines recommend testing starting at 45 for those at average risk. To stop colon cancer, it’s important to know when and how to ...
Jeff Smith was dumbfounded when he received a colon cancer screening kit in the mail. The 68-year-old Minnesota man hadn't asked for the Cologuard test, and his doctor hadn't mentioned anything about ...
For 10% of colorectal cancer patients, hereditary factors play a role, with higher percentages among younger patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results